Recombinant Human ITIH4 His-tag Protein, CF

2 μg/lane of Recombinant Human ITIH4 His-tag was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a band at 115 kDa under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ITIH4 His-tag Protein, CF Summary

• Details of Functionality: Bioassay data are not available.
• Source: Chinese Hamster Ovary cell line, CHO-derived human ITIH4 protein
  Glu29-Leu930, with a C-terminal 6-His tag
• Accession #: AAI36394.1
• N-terminal Sequence: Glu29
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 101 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 113-117 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ITIH4 His-tag Protein, CF

• DKFZp686G21125
• gp120
• H4P
• heavy chain-like, 1
• IHRP
• inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein)
• inter-alpha-trypsin inhibitor family heavy chain-related protein
• inter-alpha-trypsin inhibitor heavy chain H4
• ITIH4
• ITI-HC4
• ITIHL1
• PK120
• PK-120
• plasma kallikrein-sensitive glycoprotein 120
• PRO1851

Background

Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), also known as plasma kallikrein sensitive glycoprotein 120 (PK-120 or gp120), is a single chain protein that is synthesized mainly in liver and circulates at high levels in the plasma (1). ITIH4 can be processed by plasma kallikrein to 35kDa and 70 kDa fragments (1). ITIHs can be incorporated into inter-alpha-inhibitor complex with two HC linked to bikunin via chondroition sulfate (2,3) or associated with hyaluronan (HA) (3). Although the N-terminal 70kD fragment of ITIH4 contains a von-Willebrand type A domain and displays significant sequence similarity with other ITIHs (2,4), ITIH4 is the only member of the family with a kallikrein-sensitive domain in the c-terminus (1) and is not capable of complexing with bikunin (2,5). The unprocessed or 70kD fragment may bind to HA leading to stabilization of the extracellular matrix as for other HC (1,6). ITIH4 is up-regulated in acute inflammation (7) through interleukins (8). The 35kDa fragment is overexpressed in oestrogen-related conditions of select cancers and pregnancy (9) where increased plasma kallikrein can lead to cleavage and increased expression of pro-inflammatory cytokines while the long isoform of ITIH leads to upregulation of anti-inflammatory cytokines (10). ITIH4 is implicated as a diagnostic and prognostic marker in several diseases including hepatocellular carcinoma with NAFLD (11), acute lymphoblastic leukemia (12), colorectal adenoma (13) and Alzheimer's (14).

1. Nishimura, H. et al. (1995) FEBS Lett. 357:207.
2. Salier, JP et al. (1996) Biochem. J. 315:1.
3. Zhuo, L. et al. (2004) J. Biol. Chem. 279:38079.
4. Jean, L. et al. (1997) Genomics 41:139.
5. Hashimoto, K. et al. (1996) J. Biochem. 119:577.
6. Baranova. N.S et al. (2013) J. Biol. Chem. 288:29642.
7. Gonzalez-Ramon, N. et al. (1995) FEBS Lett. 371:227.
8. Daveau, M. et al. (1993) Biochem. J. 292:485.
9. Mohamed, E. et al. (2013) Biomarker Research 1:19.
10. Li, L. et al. (2018) EBioMedicine 37:535.
11. Nakamura, N. et al. (2019) BMC Cancer 19:621.
12. Guo, L. et al. (2019) Onco. Targets Ther. 12:3859.
13. Ivancic, M.M. et al. (2019) Proc. Natl. Acad. Sci. USA 116:8471.
14. Shi, X. et al. (2019) J. Alzheimers Dis. 68:1667.

Bioinformatics

• Uniprot:
  • AAI36394.1()